65,437 trials
Carcinoma · Metastatic Pancreatic Adenocarcinoma
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) in Dose Escalation Phase — 7; 7; 3; 8…
Healthy Volunteers
Primary: Part 1, Cmax: Maximum Observed Plasma Concentration for Soticlestat When Administered Alone and With Itraconazole — 1310; 1527 nanogram per milliliter (ng/mL)
Leukemia, Myeloid, Acute
Primary: Phase I: Maximum Tolerated Dose (MTD) of Volasertib in Combination With LDAC (Schedule A) and Volasertib Monotherapy (Schedule B) — 350; 450 milligram (mg)
Heart Failure
Primary: CRT Response Rate — 918; 312; 328 Participants
Vocal Cord Function in Neck Procedures
Primary: Frequency of Congruence of Nerve Integrity and Vocal Cord Functions — 68; 13; 17; 10 nerves at risk
Ileostomy
Primary: Trans Epidermal Water Loss After Test of Patches. — 45.8; 22.9; 36.8; 19.6 g/m^2/h
Migraine · Major Depressive Disorder
Primary: Change From Baseline in Monthly Average Number of Migraine Days During the 12-Week DB Treatment Phase After the First Dose of Study Drug — -2.9; -5.1 days — p=<0.0001
Ocular Physiology
Primary: Proportion of Eyes With Grade 3 or Higher Slit Lamp Findings — 0; 0 proportion of eyes
Breast, Cervical or Colorectal Cancer Screening Needed
Primary: Percentage of Participants Who Received All Needed Screening and Any Needed Screening Across the Three Randomized Arms — 57; 118; 19; 110 Participants
Healthy
Primary: Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) for Ethinyl Estradiol — 812.3; 823.9…
Depression · Inflammation
Primary: IL-6 Levels — 5.25; 18.24; 3.69; 6.84 pg/mL — p=.44
Post Operative Pain · Hyperalgesia
Primary: the Extent of Hyperalgesia Area Proximal to Surgical Wound — 19.5; 14.68; 15.28; 11.04 cm
HEAD & NECK Cancer
Primary: To Explore if Ribavirin Therapy for 2 Weeks Decreases Tumor Expression — 4; 2; 3 Participants
Chronic Cough
Primary: Model-Based Geometric Mean Ratio (GMR) of 24-Hour Coughs Per Hour at Week 24 — 0.47; 0.51 Ratio — p=0.713
Nurse Delivered Counseling · Emotional Distress
Primary: Mean IDAS-GD Score at 4 Weeks (End of Treatment) and 8 Weeks (Follow up) — 46.12; 51.10; 40.11; 42.39 score on a scale — p=<0.05